Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias

Journal of Clinical Psychiatry

Volumn 66, Issue 5, 2005, Pages 633-637

  Aarsland, Dag ^a   Perry, Robert ^b   Larsen, Jan P ^a   McKeith, Ian G ^b   O'Brien, John T ^b   Perry, Elaine K ^b   Burn, David ^b   Ballard, Clive G ^c,d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; CONFUSION; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMOBILIZATION; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; NEUROFIBRILLARY TANGLE; NEUROLEPTIC SENSITIVITY REACTION; NEUROPATHOLOGY; OBSERVATION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL;

EID: 19544378167     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v66n0514     Document Type: Article

References (34)

1. Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999;156:1039-1045
2. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745
3. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, et al. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003;74:720-724
4. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678
5. Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease [letter]. Lancet 1998;351:1032-1033
6. Imamura T, Hirono N, Hashimoto M, et al. Clinical diagnosis of dementia with Lewy bodies in a Japanese dementia registry. Dement Geriatr Cogn Disord 1999;10:210-216
7. Sadek J, Rockwood K. Coma with accidental single dose of an atypical neuroleptic in a patient with Lewy body dementia [letter]. Am J Geriatr Psychiatry 2003;11:112-113
8. Piggott MA, Perry EK, Marshall EF, et al. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiatry 1998;44:765-774
9. The Movement Disorder Society Task Force. Drugs to treat dementia and psychosis: management of Parkinson's disease. Mov Disord 2002;17 (suppl 4):S120-S127
10. Sato Y, Asoh T, Metoki N, et al. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:574-576
11. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392
12. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536
13. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411
14. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403
15. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586-1590
16. Tandberg E, Larsen JP, Nessler EG, et al. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995;10:541-549
17. Hoehn MH, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442
18. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058
19. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), pt 2: standardization of the neuropathologic assessment of Aizheimer's disease. Neurology 1991;41:479-486
20. McKhann G, Drachman D, Holstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
21. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242-251
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revision. Washington DC: American Psychiatric Association; 1987
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
24. Mattis S. Dementia Rating Scale. In: Bellak L, Karasu TB, eds. Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, NY: Grune & Stratton; 1976:108-121
25. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386-2391
26. Lucas JA, Ivnik RJ, Smith GE, et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exp Neuropsychol 1998;20:536-547
27. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59:1714-1720
28. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
29. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259
30. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003;18:510-514
31. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036
32. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in autopsy confirmed prospectively studied patients with dementia with Lewy bodies (DLB). Am J Psych 2004;161:843-849
33. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-210
34. Ueda M, Hamamoto M, Nagayama H, et al. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001;71:111-113